Kristin Baird, M.D.
NPI 1013900539 · Dermatology Physician · Longmont, CO
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1013900539
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Female
- Sole proprietor
- Yes
- License
- 40150 (CO)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
2,735 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 1,354 | $7 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 470 | $91 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 311 | $45 |
| Destruction of Skin Growth, 1-14 Growths17110 | 309 | $116 |
| Biopsy of Related Skin Growth, First Growth11102 | 129 | $74 |
| Destruction of Precancer Skin Growth, 15 Or More Growths17004 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 8 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Triamcinolone Acetonide | 31 | 27 |
| Clobetasol Propionate | 22 | 17 |
| Fluorouracil | 21 | 21 |
| Ketoconazole | 20 | — |
| Minoxidil | 19 | — |
| Valacyclovir Hclbrand: Valacyclovir | 15 | — |
| Adalimumabbrand: Humira Pen | 13 | — |
| Ciclopirox Olamine |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$106 across 4 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-08-30
- Last updated
- 2011-11-10
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.